RE: Prev M&A3 Feb 2023 08:04
'AstraZeneca acquired a 55% stake in the company at a valuation of $7 billion, including milestone payments. Acerta Pharma’s flagship drug is estimated to achieve potential annual sales in excess of $5 billion globally, with the company now serving as AstraZeneca’s haematology R&D unit2.'